DefiniGEN secures £3.3m in funding led by BGF to scale operations
BGF led the round with participation from 24Haymarket to support US expansion and site growth.
DefiniGEN provides human cell products and services, creating predictive disease cell models for preclinical research and drug development.
DefiniGEN has secured £3.3m in a funding round led by BGF, with participation from existing backer 24Haymarket. The company will use the capital to expand its US footprint, scale up its Cambridge facility, and develop its gene-editing capabilities.
Born as a spin-out from the University of Cambridge, DefiniGEN specialises in producing predictive disease cell models using induced pluripotent stem cells. These models assist biopharmaceutical companies in screening potential drug candidates more efficiently, particularly in therapeutic areas such as liver disease.
From the founder
"Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth."
Marcus Yeo
CEO at DefiniGEN
Investor perspective
"DefiniGEN has a strong technology platform, differentiated IP, significant commercial validation and a platform that we believe is ready to support strong growth."
Lucy Edwardes-Jones
Investor, BGF
Use of funds
- 01Expand into international markets
- 02Build out infrastructure
- 03Fund research and development
